HPV-positive oropharyngeal cancer

LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer

Retrieved on: 
Monday, September 18, 2023
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Oropharyngeal cancer, Progression-free survival, Head, Multimedia, HPV-positive oropharyngeal cancer, Patient, Poly, Gustave Roussy, Phase, Safety, Pharmaceutical industry, Vaccine

LinKinVax, a clinical-stage biotechnology company focusing on innovative protein-based vaccines, and Gustave Roussy, the leading cancer centre in Europe ranked third Best Cancer Hospital in the world, announced the treatment at Gustave Roussy of the first patient in a Phase I/IIa clinical study with CD40HVac, a new therapeutic vaccine candidate for HPV-positive oropharyngeal cancer.

Key Points: 
  • LinKinVax, a clinical-stage biotechnology company focusing on innovative protein-based vaccines, and Gustave Roussy, the leading cancer centre in Europe ranked third Best Cancer Hospital in the world, announced the treatment at Gustave Roussy of the first patient in a Phase I/IIa clinical study with CD40HVac, a new therapeutic vaccine candidate for HPV-positive oropharyngeal cancer.
  • This multicentre study will test 2 doses of CD40HVac using a dose escalation regimen.
  • Up to 24 patients will be recruited in this double-blind, randomised and placebo-controlled study.
  • Valérie Bouchara, Head of Clinical Operations at LinKinVax, commented: "This first administration is a major milestone in the development of our therapeutic cancer vaccine CD40HVac.

invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Nanoparticle, Workforce Investment Act of 1998, Infection, Cancer, Temperature, Prostate, Dicarboxylic acid, Messenger, CD8, SaRNA, Sino Biopharmaceutical Limited, HKEX, Trust, HPV-positive oropharyngeal cancer, Patient, RALA, HPV, Growth, Cervical cancer, Therapy, Vaccine

invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.

Key Points: 
  • invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company.
  • The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and saRNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response.
  • Prof. Helen McCarthy, Chief Executive Officer and Founder of pHion, said:
    “At pHion Therapeutics, it is our mission to pioneer next generation, first-in-class vaccines for infectious disease and oncology through stealth-like delivery of mRNA.
  • We look forward to seeing PTX_V1 reach the clinic and supporting this program into the next stages of its development.”

Head & Neck Cancer Alliance Holds Inaugural Move-a-Thon in April 2023

Retrieved on: 
Tuesday, March 14, 2023
Rehabilitation, Nasal cavity, Otorhinolaryngology, Head, Tennis, HPV, Dance, Eating, Athlete, Mouth, Caregiver, Larynx, Patient, Incidence, VIP, Pharynx, Head and Neck Cancer Alliance, Cycling, Head and neck cancer, Walking, Participation, Cancer, Gland, HPV-positive oropharyngeal cancer, Singing, Research, Swimming, HNCA, Survivor, Cooking, EST, Entertainment, Nightclub, Vaccine, Mobile phone, Dentistry

CHARLESTON, S.C., March 14, 2023 /PRNewswire-PRWeb/ -- The Head & Neck Cancer Alliance (HNCA) will hold its inaugural national Head and Neck Cancer (HNCA) Move-A-Thon in April 2023, which is also Head & Neck Cancer Awareness Month. The HNCA Move-A-Thon is a virtual interactive event that invites the public to raise funds and awareness for head and neck cancers by setting a personal "move" goal to make a difference in the lives of cancer patients, survivors, caregivers and families!

Key Points: 
  • CHARLESTON, S.C., March 14, 2023 /PRNewswire-PRWeb/ -- The Head & Neck Cancer Alliance (HNCA) will hold its inaugural national Head and Neck Cancer (HNCA) Move-A-Thon in April 2023, which is also Head & Neck Cancer Awareness Month .
  • The HNCA Move-a-Thon in April 2023 will happen concurrently with HNCA's 25th annual nationwide campaign – "Oral, Head & Neck Cancer Awareness Week" – to be held April 16 - 22, 2023.
  • During "Oral, Head and Neck Cancer Awareness Week," HNCA promotes a high volume of free oral, head and neck cancer screenings all over the world, plus educational talks, and other awareness programs.
  • The Head & Neck Cancer Alliance's mission is to advance prevention, detection, treatment and rehabilitation of oral, head and neck cancer through public awareness, research and advocacy.

Throat & Tonsil Cancer Survivors Actor Rob Paulsen and Green Day's Jason White Urge Public to Attend Free Local Screenings during Oral, Head & Neck Cancer Awareness Week

Retrieved on: 
Thursday, March 9, 2023
Neutron, HOLIDAY, Cancer, III, Nasal cavity, Pharynx, Mississippi Delta, White, Survivor, Incidence, Eating, News, Research, Head and Neck Cancer Alliance, Rehabilitation, Green Day, Grammy Awards, Mouth, Inauguration, Radio, Otorhinolaryngology, Risk, HNCA, Vaccination, HPV-positive oropharyngeal cancer, Survival, Human, Rock and Roll Hall of Fame, Immunotherapy, Jimmy Neutron, EST, Record, HPV, Oral cancer, GREEN, Larynx, Gland, CATS, Dentistry, Mobile phone, Vaccine, San Francisco Bay Area, Brain, Head

CHARLESTON, S.C., March 9, 2023 /PRNewswire-PRWeb/ -- Rob Paulsen, voice-over actor, and Jason White, Green Day guitarist, – both neck cancer survivors – are joining forces with the Head and Neck Cancer Alliance (HNCA) to promote the benefits of screenings and early detection during HNCA's 25th annual nationwide campaign – "Oral, Head & Neck Cancer Awareness Week" – to be held April 16 - 22, 2023.

Key Points: 
  • During "Oral, Head and Neck Cancer Awareness Week," HNCA promotes a high volume of free oral, head and neck cancer screenings all over the world, plus educational talks, and other awareness programs.
  • Head and neck cancer is a group of cancers affecting the oral cavity (mouth), larynx (voice box), pharynx (throat), sinuses, nasal cavity, or salivary glands.
  • More than 65,000 Americans are diagnosed with head and neck cancer every year, with 14,600 lives lost.
  • The Head & Neck Cancer Alliance's mission is to advance prevention, detection, treatment and rehabilitation of oral, head and neck cancer through public awareness, research and advocacy.

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer

Retrieved on: 
Thursday, January 19, 2023
Research, Infectious Diseases, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, HPV-positive oropharyngeal cancer, HPV, B cell, Anal cancer, Heart, Safety, Gustave Roussy, Poly, Korea Disease Control and Prevention Agency, Cervical cancer, Partnership, Immune system, Patient, Cancer, Head, CDC, Vaginal cancer, Progression-free survival, Vaccine

Several exploratory objectives are also planned to estimate progression-free survival and overall survival.

Key Points: 
  • Several exploratory objectives are also planned to estimate progression-free survival and overall survival.
  • It represents a bridge between basic research and clinical research designed to accelerate innovation for the benefit of patients.
  • Together with Gustave Roussy, we look forward to making what we hope will be a major contribution to the treatment of HPV related cancers".
  • We hope that this first project will be inaugural of a long-standing and synergistic collaboration between LinKinVax and Gustave Roussy".

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

Retrieved on: 
Wednesday, November 2, 2022
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Marketing, PFS, Vaccination, HPV-positive oropharyngeal cancer, Avelumab, Progression-free survival, Department, Human, Curie Institute, RECIST, Risk, NEC, Doctor of Philosophy, TME, NYSE, Merck Group, PFE, Immunotherapy, Immune system, Cell, HPV, Safety, MVA, TNG, Pfizer, Patient, Neoplasm, Artificial intelligence, Gene, ESMO, Transgene, SITC, Cancer, Liver disease, Phase, HPV16, HIV disease progression rates, AMF, AstraZeneca, Drug development, Potyvirus, Tumor microenvironment, PD-L1, Curie Institute (Paris), Principal, E7, DCR, Precision medicine, Forward-looking statement, ORR, Vaccine, Pharmaceutical industry, Euronext

The trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE), which are providing avelumab for the trial.

Key Points: 
  • The trial is being conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE), which are providing avelumab for the trial.
  • Avelumab is co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc. Transgene will continue to be the sponsor of the trial and conduct the trial.
  • Avelumab is not approved alone or in combination for the treatment of HPV16-positive anogenital tumors in any region.
  • The combination of TG4001 and avelumab demonstrated anti-tumor activity (22% ORR) in patients with previously treated recurrent and/or metastatic HPV-related cancers (including patients with oropharyngeal cancers and anogenital cancers).

Kovina Therapeutics Receives NIH Grant to Develop Human Papillomavirus E6 Inhibitors to Treat Oropharyngeal Cancers

Retrieved on: 
Tuesday, November 1, 2022
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Survival, CEO, Human papillomavirus infection, HPV-positive oropharyngeal cancer, Research, National Institute of Dental and Craniofacial Research, National Institute, NIH, Disease, Head, HPV, Oropharyngeal cancer, Incidence, NIDCR, Cancer, Therapy, Profile, SBIR, CSO, Biotechnology, Science, Small Business Innovation Research, Pharmaceutical industry, Vaccine

Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections.

Key Points: 
  • Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections.
  • Oropharyngeal cancers arising from HPV infections are increasing across many age groups and around the world.
  • This SBIR grant funds testing of our novel HPV inhibitory compounds for activity in preclinical models of oropharyngeal cancer.
  • Kovina Therapeutics is a biotechnology company developing first-in-class antiviral therapies to treat cancers and premalignant infections caused by Human Papillomavirus (HPV).

The Oral Cancer Foundation announced that Dr. Niven R. Narain has joined its Scientific Advisory Board

Retrieved on: 
Wednesday, March 30, 2022
Disease, Drug development, Organization, National Science Advisory Board for Biosecurity, Population, No, Saint John's University, Harvard Law School, Advisory board, CNS, Breast, Research, Science Translational Medicine, Oral cancer, HPV-positive oropharyngeal cancer, Incidence, AI, Health, Artificial intelligence, Bioethics, Industry, Science Advisory Board, Technology, Biology, NIH, The Wall Street Journal, Goal, BBC, Prostate cancer, CNN, Student, The New York Times, Foundation, The Advisory Board Company, Fox Business, University, Patient, CNBC, United States Department of Defense, Pharmaceutical industry, Biotechnology

Under his leadership, BERG has fueled a deep pipeline of assets in oncology, metabolic, rare, immune, and CNS diseases.

Key Points: 
  • Under his leadership, BERG has fueled a deep pipeline of assets in oncology, metabolic, rare, immune, and CNS diseases.
  • "We are very pleased to have Dr. Narain become a member of our OCF Science Advisory Board," said Brian Hill, Oral Cancer Foundation Founder and Executive Director.
  • Dr. Narain is a member of the NASA/Gene Lab Steering Committee and an advisor to US Department of Defense leadership on breast and prostate cancer.
  • "It is an honor to be selected to serve on the Oral Cancer Foundation's Science Advisory Board and to assist in the outstanding work the Foundation does to support oral cancer patients and oral cancer research," said Dr. Narain.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 1, 2021
Safety, Head, RCC, Neoplasm, HPV, Partnership, Adenosine, Society, NMPA, CDE, Degenerative disease, Clinical trial, COVID-19, IND, Program, HPV-positive oropharyngeal cancer, Extranodal NK/T-cell lymphoma, nasal type, ATP, Immune system, Autoimmunity, GLOBE, SITC, Kidney cancer, Antigen, Tumor microenvironment, Death, BTK, Total, Leukemia, Security (finance), T-cell lymphoma, Company, Investment, ITK, EBV, Immunotherapy, Virus, Large-cell lung carcinoma, Exercise, Center, Immunity, HNSCC, A2A, Nasdaq, Sale, Pembrolizumab, Board of directors, NSCLC, Cancer, Patient, Lymphocyte, Time, Forward-looking statement, NK, CD73, Research, Pharmaceutical industry, Vaccine

BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2021.

Key Points: 
  • BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2021.
  • We anticipate that the results will be presented at the annual meeting of the Society of Immunotherapy of Cancer (SITC) in November 2021.
  • The endpoint of the clinical trial is response rate and initial results are anticipated in 2022.
  • Angel Pharmaceuticals was launched through a collaboration with U.S.-based Corvus Pharmaceuticals and investments from investors in China.

Stand Up To Cancer Announces New Research Team Focused On Head And Neck Cancers

Retrieved on: 
Thursday, October 28, 2021
Woman, Rockefeller University, Head, American Head, Cancer, MD, Larynx, Research, Quality of life, SU2C, Disease, Tongue, Exocrine gland, National Cancer Institute, Bone marrow failure, Head and Neck Cancer Alliance, Survival, Organization, Stand Up, FAC, HPV, Patient, Yale Cancer Center, Thyroid, Stand Up to Cancer, Medicine, CEO, RN, Cervical cancer, Man, Awareness, Multimedia, Burtness, Nasal cavity, HPV-positive oropharyngeal cancer, Survivor, Throat, Pharynx, DNA, Toxicity, Doctor of Philosophy, Incidence, Entertainment Industry Foundation, Neck, Mouth, Fanconi anemia, Vaccine, Dentistry, Management, Pharmaceutical industry

LOS ANGELES, Oct. 28, 2021 /PRNewswire/ -- Stand Up To Cancer (SU2C) today announced the Stand Up To CancerFanconi Anemia Research FundFarrah Fawcett Foundation Head and Neck Cancer Research Team.

Key Points: 
  • LOS ANGELES, Oct. 28, 2021 /PRNewswire/ -- Stand Up To Cancer (SU2C) today announced the Stand Up To CancerFanconi Anemia Research FundFarrah Fawcett Foundation Head and Neck Cancer Research Team.
  • The team has been awarded $3.25 million over three years to advance therapies, support new approaches and improve patient outcomes for head and neck cancers.
  • The American Head and Neck Society and the Head and Neck Cancer Alliance have each provided $125,000 to support the team.
  • This is also the first time SU2C has worked with a nonprofit foundation that is not directly focused on cancer research the Fanconi Anemia Research Fund.